Anticancer activity of rutin and its combination with ionic liquids on renal cells
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.1/13708 |
Resumo: | The renal cell carcinoma (RCC) is the most common type of kidney cancer. Identifying novel and more effective therapies, while minimizing toxicity, continues to be fundamental in curtailing RCC. Rutin, a bioflavonoid widely found in nature, has shown promising anticancer properties, but with limited applicability due to its poor water solubility and pharmacokinetics. Thus, the potential anticancer effects of rutin toward a human renal cancer cell line (786-O), while considering its safety in Vero kidney cells, was assessed, as well as the applicability of ionic liquids (ILs) to improve drug delivery. Rutin (up to 50 µM) did not show relevant cytotoxic effects in Vero cells. However, in 786-O cells, a significant decrease in cell viability was already observed at 50 µM. Moreover, exposure to rutin caused a significant increase in the sub-G1 population of 786-O cells, reinforcing the possible anticancer activity of this biomolecule. Two choline-amino acid ILs, at non-toxic concentrations, enhanced rutin's solubility/loading while allowing the maintenance of rutin's anticancer effects. Globally, our findings suggest that rutin may have a beneficial impact against RCC and that its combination with ILs ensures that this poorly soluble drug is successfully incorporated into ILs-nanoparticles hybrid systems, allowing controlled drug delivery. |
id |
RCAP_8f75515f9d9cf151621556150fa5ad9e |
---|---|
oai_identifier_str |
oai:sapientia.ualg.pt:10400.1/13708 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Anticancer activity of rutin and its combination with ionic liquids on renal cellsRutinRenal cancer786-O cellsVero cellsCytotoxicityCell cycleIonic liquidsSolubilityILs–nanoparticles hybrid systemThe renal cell carcinoma (RCC) is the most common type of kidney cancer. Identifying novel and more effective therapies, while minimizing toxicity, continues to be fundamental in curtailing RCC. Rutin, a bioflavonoid widely found in nature, has shown promising anticancer properties, but with limited applicability due to its poor water solubility and pharmacokinetics. Thus, the potential anticancer effects of rutin toward a human renal cancer cell line (786-O), while considering its safety in Vero kidney cells, was assessed, as well as the applicability of ionic liquids (ILs) to improve drug delivery. Rutin (up to 50 µM) did not show relevant cytotoxic effects in Vero cells. However, in 786-O cells, a significant decrease in cell viability was already observed at 50 µM. Moreover, exposure to rutin caused a significant increase in the sub-G1 population of 786-O cells, reinforcing the possible anticancer activity of this biomolecule. Two choline-amino acid ILs, at non-toxic concentrations, enhanced rutin's solubility/loading while allowing the maintenance of rutin's anticancer effects. Globally, our findings suggest that rutin may have a beneficial impact against RCC and that its combination with ILs ensures that this poorly soluble drug is successfully incorporated into ILs-nanoparticles hybrid systems, allowing controlled drug delivery.Fundação para a Ciência e Tecnologia (FCT, Portugal): UID/DTP/04567/2019/ UIDB/00100/2020/ UIDB/04565/2020. ALIES grant PADDIC 2018-2019MDPISapientiaCaparica, RitaJúlio, AnaAraújo, Maria Eduarda MachadoBaby, André RolimFonte, PedroCosta, João GuilhermeSantos de Almeida, Tânia2020-04-15T09:34:23Z2020-022020-02-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/13708eng2218-273Xhttps://doi.org/10.3390/biom10020233info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T10:25:53Zoai:sapientia.ualg.pt:10400.1/13708Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:04:50.505449Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Anticancer activity of rutin and its combination with ionic liquids on renal cells |
title |
Anticancer activity of rutin and its combination with ionic liquids on renal cells |
spellingShingle |
Anticancer activity of rutin and its combination with ionic liquids on renal cells Caparica, Rita Rutin Renal cancer 786-O cells Vero cells Cytotoxicity Cell cycle Ionic liquids Solubility ILs–nanoparticles hybrid system |
title_short |
Anticancer activity of rutin and its combination with ionic liquids on renal cells |
title_full |
Anticancer activity of rutin and its combination with ionic liquids on renal cells |
title_fullStr |
Anticancer activity of rutin and its combination with ionic liquids on renal cells |
title_full_unstemmed |
Anticancer activity of rutin and its combination with ionic liquids on renal cells |
title_sort |
Anticancer activity of rutin and its combination with ionic liquids on renal cells |
author |
Caparica, Rita |
author_facet |
Caparica, Rita Júlio, Ana Araújo, Maria Eduarda Machado Baby, André Rolim Fonte, Pedro Costa, João Guilherme Santos de Almeida, Tânia |
author_role |
author |
author2 |
Júlio, Ana Araújo, Maria Eduarda Machado Baby, André Rolim Fonte, Pedro Costa, João Guilherme Santos de Almeida, Tânia |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Sapientia |
dc.contributor.author.fl_str_mv |
Caparica, Rita Júlio, Ana Araújo, Maria Eduarda Machado Baby, André Rolim Fonte, Pedro Costa, João Guilherme Santos de Almeida, Tânia |
dc.subject.por.fl_str_mv |
Rutin Renal cancer 786-O cells Vero cells Cytotoxicity Cell cycle Ionic liquids Solubility ILs–nanoparticles hybrid system |
topic |
Rutin Renal cancer 786-O cells Vero cells Cytotoxicity Cell cycle Ionic liquids Solubility ILs–nanoparticles hybrid system |
description |
The renal cell carcinoma (RCC) is the most common type of kidney cancer. Identifying novel and more effective therapies, while minimizing toxicity, continues to be fundamental in curtailing RCC. Rutin, a bioflavonoid widely found in nature, has shown promising anticancer properties, but with limited applicability due to its poor water solubility and pharmacokinetics. Thus, the potential anticancer effects of rutin toward a human renal cancer cell line (786-O), while considering its safety in Vero kidney cells, was assessed, as well as the applicability of ionic liquids (ILs) to improve drug delivery. Rutin (up to 50 µM) did not show relevant cytotoxic effects in Vero cells. However, in 786-O cells, a significant decrease in cell viability was already observed at 50 µM. Moreover, exposure to rutin caused a significant increase in the sub-G1 population of 786-O cells, reinforcing the possible anticancer activity of this biomolecule. Two choline-amino acid ILs, at non-toxic concentrations, enhanced rutin's solubility/loading while allowing the maintenance of rutin's anticancer effects. Globally, our findings suggest that rutin may have a beneficial impact against RCC and that its combination with ILs ensures that this poorly soluble drug is successfully incorporated into ILs-nanoparticles hybrid systems, allowing controlled drug delivery. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-04-15T09:34:23Z 2020-02 2020-02-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.1/13708 |
url |
http://hdl.handle.net/10400.1/13708 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
2218-273X https://doi.org/10.3390/biom10020233 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133286541295616 |